Psychosis - Pipeline Review, H1 2016

  • ID: 3734745
  • Report
  • 69 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Evotec AG
  • Gabather AB
  • Merck & Co., Inc.
  • MORE
Psychosis - Pipeline Review, H1 2016

Summary

‘Psychosis - Pipeline Review, H1 2016’, provides an overview of the Psychosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psychosis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psychosis
- The report reviews pipeline therapeutics for Psychosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Psychosis therapeutics and enlists all their major and minor projects
- The report assesses Psychosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Psychosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Psychosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Evotec AG
  • Gabather AB
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Psychosis Overview

Therapeutics Development

Pipeline Products for Psychosis - Overview

Psychosis - Therapeutics under Development by Companies

Psychosis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Psychosis - Products under Development by Companies

Psychosis - Companies Involved in Therapeutics Development

Acadia Pharmaceuticals Inc.

Addex Therapeutics Ltd

Evotec AG

Gabather AB

Glenmark Pharmaceuticals Ltd.

Heptares Therapeutics Limited

Integrative Research Laboratories Sweden AB

Merck & Co., Inc.

Newron Pharmaceuticals S.p.A.

Reviva Pharmaceuticals Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc.

Wuhan Docan Pharmaceutical Co., Ltd

Psychosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ADX-88178 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CB-0306 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile

Product Description

Mechanism of Action

R&D Progress

evenamide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gaaba-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IRL-790 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pimavanserin tartrate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SEP-39 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Psychosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Psychosis - Recent Pipeline Updates

Psychosis - Dormant Projects

Psychosis - Discontinued Products

Psychosis - Product Development Milestones

Featured News & Press Releases

Mar 29, 2016: FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID(Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks

Jan 29, 2016: ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID(Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis

Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch

Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis

Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin

Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting

Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis

May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis

Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Psychosis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H1 2016

Psychosis - Pipeline by Addex Therapeutics Ltd, H1 2016

Psychosis - Pipeline by Evotec AG, H1 2016

Psychosis - Pipeline by Gabather AB, H1 2016

Psychosis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016

Psychosis - Pipeline by Heptares Therapeutics Limited, H1 2016

Psychosis - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016

Psychosis - Pipeline by Merck & Co., Inc., H1 2016

Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016

Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H1 2016

Psychosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016

Psychosis - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016

Psychosis - Pipeline by Wuhan Docan Pharmaceutical Co., Ltd, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Psychosis Therapeutics - Recent Pipeline Updates, H1 2016

Psychosis - Dormant Projects, H1 2016

Psychosis - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Psychosis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Acadia Pharmaceuticals Inc.
Addex Therapeutics Ltd
Evotec AG
Gabather AB
Glenmark Pharmaceuticals Ltd.
Heptares Therapeutics Limited
Integrative Research Laboratories Sweden AB
Merck & Co., Inc.
Newron Pharmaceuticals S.p.A.
Reviva Pharmaceuticals Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc.
Wuhan Docan Pharmaceutical Co., Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll